ArticleScientific reports2025
Functionalized MoS
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, molecular dynamics (MD) simulations were employed to investigate the adsorption mechanisms of the chemotherapeutic drug gemcitabine (GEM) on pristine and functionalized molybdenum disulfide (MoS₂) nanosheets. The functionalization of MoS₂ was achieved by incorporating polyethyleneimine (PEI), polyethylene glycol (PEG), and cytosine-phosphate-guanine (CPG) groups, enhancing the material's drug adsorption capacity. Our simulations reveal that the MoS₂/CPG-PEI-PEG system exhibits a significantly higher affinity for GEM compared to pristine MoS₂, with interaction energies reaching -236 kJ/mol, driven primarily by van der Waals (vdW) interactions and electrostatic forces. Metadynamics simulations further confirm that the global minimum free energy for the functionalized system is approximately -237 kJ/mol, compared to -199 kJ/mol for pristine MoS₂. Radial distribution function (RDF) analysis and density profiles highlight stronger drug-substrate interactions and reduced solvent exposure in the functionalized system, which also exhibits lower drug mobility, suggesting more stable adsorption. These findings are supported by experimental data, demonstrating that functionalized MoS₂ nanosheets offer a promising platform for enhancing drug delivery systems. This work underscores the importance of surface functionalization in optimizing drug adsorption and stability, offering valuable insights for the development of more efficient nanomaterials in targeted drug delivery applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.